Biohaven Reports Fourth Quarter and Full Year 2022 Financial Results and Reports Recent Business Developments
Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global (ex-China)...
United States Dana Farber Cancer Institute United Kingdom Mike Beyer Jennifer Porcelli Matthew Buten
Source: prnewswire.com